Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.

Chiaretti S, Messina M, Grammatico S, Piciocchi A, Fedullo AL, Di Giacomo F, Peragine N, Gianfelici V, Lauretti A, Bareja R, Martelli MP, Vignetti M, Apicella V, Vitale A, Li LS, Salek C, Elemento O, Inghirami G, Weinstock DM, Guarini A, Foà R.

Br J Haematol. 2018 Apr 19. doi: 10.1111/bjh.15251. [Epub ahead of print]

PMID:
29675955
2.

Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients.

De Clara E, Gourvest M, Ma H, Vergez F, Tosolini M, Dejean S, Demur C, Delabesse E, Recher C, Touriol C, Martelli MP, Falini B, Brousset P, Bousquet M.

Haematologica. 2017 Oct;102(10):1718-1726. doi: 10.3324/haematol.2017.171645. Epub 2017 Jul 4.

3.

Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling.

Tripodo C, Burocchi A, Piccaluga PP, Chiodoni C, Portararo P, Cappetti B, Botti L, Gulino A, Isidori A, Liso A, Visani G, Martelli MP, Falini B, Pandolfi PP, Colombo MP, Sangaletti S.

Cancer Res. 2017 Jul 1;77(13):3685-3699. doi: 10.1158/0008-5472.CAN-17-1098. Epub 2017 May 23.

PMID:
28536276
4.

Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin.

Brunetti L, Di Battista V, Venanzi A, Schiavoni G, Martelli MP, Ascani S, Mecucci C, Tiacci E, Falini B.

Leukemia. 2017 May;31(5):1238-1240. doi: 10.1038/leu.2017.38. Epub 2017 Jan 23. No abstract available.

PMID:
28111467
5.

All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature.

Forghieri F, Bigliardi S, Quadrelli C, Morselli M, Potenza L, Paolini A, Colaci E, Barozzi P, Zucchini P, Riva G, Vallerini D, Lagreca I, Marasca R, Narni F, Venditti A, Martelli MP, Falini B, Lo Coco F, Amadori S, Luppi M.

Clin Case Rep. 2016 Oct 24;4(12):1138-1146. eCollection 2016 Dec.

6.

BRAF V600E mutation in hairy cell leukemia: from bench to bedside.

Falini B, Martelli MP, Tiacci E.

Blood. 2016 Oct 13;128(15):1918-1927. Epub 2016 Aug 23. Review.

7.

Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.

Falini B, Martelli MP.

Best Pract Res Clin Haematol. 2015 Jun-Sep;28(2-3):90-7. doi: 10.1016/j.beha.2015.10.005. Epub 2015 Oct 22. Review.

PMID:
26590764
8.

Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia.

Falini B, Brunetti L, Martelli MP.

N Engl J Med. 2015 Sep 17;373(12):1180-2. doi: 10.1056/NEJMc1509584. No abstract available.

9.

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS.

N Engl J Med. 2015 Oct 29;373(18):1733-47. doi: 10.1056/NEJMoa1506583. Epub 2015 Sep 9.

10.

Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.

Falini B, Sportoletti P, Brunetti L, Martelli MP.

Br J Haematol. 2015 Aug;170(3):305-22. doi: 10.1111/bjh.13409. Epub 2015 Apr 19. Review.

PMID:
25891481
11.

Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.

Martelli MP, Gionfriddo I, Mezzasoma F, Milano F, Pierangeli S, Mulas F, Pacini R, Tabarrini A, Pettirossi V, Rossi R, Vetro C, Brunetti L, Sportoletti P, Tiacci E, Di Raimondo F, Falini B.

Blood. 2015 May 28;125(22):3455-65. doi: 10.1182/blood-2014-11-611459. Epub 2015 Mar 20.

12.

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.

Pettirossi V, Santi A, Imperi E, Russo G, Pucciarini A, Bigerna B, Schiavoni G, Fortini E, Spanhol-Rosseto A, Sportoletti P, Mannucci R, Martelli MP, Klein-Hitpass L, Falini B, Tiacci E.

Blood. 2015 Feb 19;125(8):1207-16. doi: 10.1182/blood-2014-10-603100. Epub 2014 Dec 5.

13.

Identification of novel DNA-damage tolerance genes reveals regulation of translesion DNA synthesis by nucleophosmin.

Ziv O, Zeisel A, Mirlas-Neisberg N, Swain U, Nevo R, Ben-Chetrit N, Martelli MP, Rossi R, Schiesser S, Canman CE, Carell T, Geacintov NE, Falini B, Domany E, Livneh Z.

Nat Commun. 2014 Nov 25;5:5437. doi: 10.1038/ncomms6437.

14.

Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.

Sportoletti P, Varasano E, Rossi R, Mupo A, Tiacci E, Vassiliou G, Martelli MP, Falini B.

Leukemia. 2015 Feb;29(2):269-78. doi: 10.1038/leu.2014.257. Epub 2014 Sep 2. Review.

PMID:
25179729
15.

Pharmacological modulation of caspase-8 in thymus-related medical conditions.

Pozzesi N, Fierabracci A, Thuy TT, Martelli MP, Liberati AM, Ayroldi E, Riccardi C, Delfino DV.

J Pharmacol Exp Ther. 2014 Oct;351(1):18-24. doi: 10.1124/jpet.114.216572. Epub 2014 Jul 24. Review.

16.

Role of caspase-8 in thymus function.

Pozzesi N, Fierabracci A, Liberati AM, Martelli MP, Ayroldi E, Riccardi C, Delfino DV.

Cell Death Differ. 2014 Feb;21(2):226-33. doi: 10.1038/cdd.2013.166. Epub 2013 Nov 22. Review.

17.

Immunophenotypic and molecular features of 'cuplike' acute myeloid leukemias.

Carluccio P, Mestice A, Pastore D, Delia M, Ricco A, Russo-Rossi A, Casieri P, Liso A, Martelli MP, Albano F, Specchia G.

Eur J Haematol. 2014 Feb;92(2):121-6. doi: 10.1111/ejh.12217.

PMID:
24138595
18.

The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model.

Sportoletti P, Varasano E, Rossi R, Bereshchenko O, Cecchini D, Gionfriddo I, Bolli N, Tiacci E, Intermesoli T, Zanghì P, Masciulli A, Martelli MP, Falzetti F, Martelli MF, Falini B.

Blood. 2013 Apr 25;121(17):3447-58. doi: 10.1182/blood-2012-08-449553. Epub 2013 Feb 22.

19.

Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.

Tiacci E, Schiavoni G, Martelli MP, Boveri E, Pacini R, Tabarrini A, Zibellini S, Santi A, Pettirossi V, Fortini E, Ascani S, Arcaini L, Inghirami G, Paulli M, Falini B.

Haematologica. 2013 Apr;98(4):635-9. doi: 10.3324/haematol.2012.078071. Epub 2013 Jan 24.

20.

Mutational landscape of AML with normal cytogenetics: biological and clinical implications.

Martelli MP, Sportoletti P, Tiacci E, Martelli MF, Falini B.

Blood Rev. 2013 Jan;27(1):13-22. doi: 10.1016/j.blre.2012.11.001. Epub 2012 Dec 20. Review.

PMID:
23261068
21.

IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas.

Falini B, Agostinelli C, Bigerna B, Pucciarini A, Pacini R, Tabarrini A, Falcinelli F, Piccioli M, Paulli M, Gambacorta M, Ponzoni M, Tiacci E, Ascani S, Martelli MP, Dalla Favera R, Stein H, Pileri SA.

Histopathology. 2012 Nov;61(5):930-41. doi: 10.1111/j.1365-2559.2012.04289.x. Epub 2012 Jun 20.

PMID:
22716304
22.

Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia.

Tiacci E, Pucciarini A, Bigerna B, Pettirossi V, Strozzini F, Martelli MP, Tabarrini A, Drexler HG, Falini B.

Blood. 2012 May 31;119(22):5332-3. doi: 10.1182/blood-2011-12-400374. No abstract available.

23.

The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia.

Tiacci E, Grossmann V, Martelli MP, Kohlmann A, Haferlach T, Falini B.

Haematologica. 2012 Jan;97(1):3-5. doi: 10.3324/haematol.2011.057901. No abstract available.

24.

Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.

Grossmann V, Tiacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W, Spanhol-Rosseto A, Klein HU, Dugas M, Schindela S, Trifonov V, Schnittger S, Haferlach C, Bassan R, Wells VA, Spinelli O, Chan J, Rossi R, Baldoni S, De Carolis L, Goetze K, Serve H, Peceny R, Kreuzer KA, Oruzio D, Specchia G, Di Raimondo F, Fabbiano F, Sborgia M, Liso A, Farinelli L, Rambaldi A, Pasqualucci L, Rabadan R, Haferlach T, Falini B.

Blood. 2011 Dec 1;118(23):6153-63. doi: 10.1182/blood-2011-07-365320. Epub 2011 Oct 19.

25.

NPM1-mutated AML: targeting by disassembling.

Falini B, Martelli MP.

Blood. 2011 Sep 15;118(11):2936-8. doi: 10.1182/blood-2011-07-366146. No abstract available.

26.

The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations.

Tiacci E, Spanhol-Rosseto A, Martelli MP, Pasqualucci L, Quentmeier H, Grossmann V, Drexler HG, Falini B.

Leukemia. 2012 Mar;26(3):554-7. doi: 10.1038/leu.2011.238. Epub 2011 Sep 9. No abstract available.

PMID:
21904384
27.

Maesopsin 4-O-beta-D-glucoside, a natural compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation and up-regulates HMOX1, SRXN1 and BCAS3 in acute myeloid leukemia.

Pozzesi N, Pierangeli S, Vacca C, Falchi L, Pettorossi V, Martelli MP, Thuy TT, Ninh PT, Liberati AM, Riccardi C, Sung TV, Delfino DV.

J Chemother. 2011 Jun;23(3):150-7.

PMID:
21742584
28.

Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?

Falini B, Gionfriddo I, Cecchetti F, Ballanti S, Pettirossi V, Martelli MP.

Blood Rev. 2011 Nov;25(6):247-54. doi: 10.1016/j.blre.2011.06.001. Epub 2011 Jul 2. Review.

PMID:
21724308
29.

BRAF mutations in hairy-cell leukemia.

Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B.

N Engl J Med. 2011 Jun 16;364(24):2305-15. doi: 10.1056/NEJMoa1014209. Epub 2011 Jun 11.

30.

Eicosapentaenoic acid demethylates a single CpG that mediates expression of tumor suppressor CCAAT/enhancer-binding protein delta in U937 leukemia cells.

Ceccarelli V, Racanicchi S, Martelli MP, Nocentini G, Fettucciari K, Riccardi C, Marconi P, Di Nardo P, Grignani F, Binaglia L, Vecchini A.

J Biol Chem. 2011 Aug 5;286(31):27092-102. doi: 10.1074/jbc.M111.253609. Epub 2011 Jun 9.

31.

Immunohistochemical surrogates for genetic alterations of CCDN1, PML, ALK, and NPM1 genes in lymphomas and acute myeloid leukemia.

Falini B, Martelli MP, Tiacci E, Ascani S, Thiede C, Pileri SA.

Best Pract Res Clin Haematol. 2010 Sep;23(3):417-31. doi: 10.1016/j.beha.2010.09.001. Epub 2010 Oct 29. Review.

PMID:
21112040
32.

New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues.

Falini B, Tiacci E, Martelli MP, Ascani S, Pileri SA.

Discov Med. 2010 Oct;10(53):281-92. Review.

33.

Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?

Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E, Haferlach T.

Blood. 2011 Jan 27;117(4):1109-20. doi: 10.1182/blood-2010-08-299990. Epub 2010 Oct 28. Review.

34.

Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes.

Barresi V, Romano A, Musso N, Capizzi C, Consoli C, Martelli MP, Palumbo G, Di Raimondo F, Condorelli DF.

Genes Chromosomes Cancer. 2010 Nov;49(11):1014-23. doi: 10.1002/gcc.20810.

PMID:
20725993
35.

Glucocorticoid-induced activation of caspase-8 protects the glucocorticoid-induced protein Gilz from proteasomal degradation and induces its binding to SUMO-1 in murine thymocytes.

Delfino DV, Spinicelli S, Pozzesi N, Pierangeli S, Velardi E, Bruscoli S, Martelli MP, Pettirossi V, Falchi L, Kang TB, Riccardi C.

Cell Death Differ. 2011 Jan;18(1):183-90. doi: 10.1038/cdd.2010.86. Epub 2010 Jul 30.

36.

CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.

Martelli MP, Pettirossi V, Thiede C, Bonifacio E, Mezzasoma F, Cecchini D, Pacini R, Tabarrini A, Ciurnelli R, Gionfriddo I, Manes N, Rossi R, Giunchi L, Oelschlägel U, Brunetti L, Gemei M, Delia M, Specchia G, Liso A, Di Ianni M, Di Raimondo F, Falzetti F, Del Vecchio L, Martelli MF, Falini B.

Blood. 2010 Nov 11;116(19):3907-22. doi: 10.1182/blood-2009-08-238899. Epub 2010 Jul 15.

37.

Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help.

Falini B, Martelli MP, Pileri SA, Mecucci C.

Haematologica. 2010 Apr;95(4):529-34. doi: 10.3324/haematol.2009.017822. No abstract available.

38.

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).

Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W, Kohlmann A, Klein HU, Vignetti M, Piciocchi A, Fazi P, Martelli MP, Vitale A, Pileri S, Miesner M, Santucci A, Haferlach C, Mandelli F, Haferlach T.

Blood. 2010 May 6;115(18):3776-86. doi: 10.1182/blood-2009-08-240457. Epub 2010 Mar 4. Erratum in: Blood. 2010 Aug 12;116(6):1017.

39.

Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.

Falini B, Sportoletti P, Martelli MP.

Curr Opin Oncol. 2009 Nov;21(6):573-81. doi: 10.1097/CCO.0b013e3283313dfa. Review.

PMID:
19770764
40.

The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues.

Sozzi G, Martelli MP, Conte D, Modena P, Pettirossi V, Pileri SA, Falini B.

Haematologica. 2009 Sep;94(9):1307-11. doi: 10.3324/haematol.2009.008045.

41.

Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy.

Falini B, Martelli MP.

Haematologica. 2009 Jul;94(7):897-900. doi: 10.3324/haematol.2009.008250. No abstract available.

42.

Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.

Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S, Nicoletti I.

Leukemia. 2009 Oct;23(10):1731-43. doi: 10.1038/leu.2009.124. Epub 2009 Jun 11. Review.

PMID:
19516275
43.

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.

Haferlach C, Mecucci C, Schnittger S, Kohlmann A, Mancini M, Cuneo A, Testoni N, Rege-Cambrin G, Santucci A, Vignetti M, Fazi P, Martelli MP, Haferlach T, Falini B.

Blood. 2009 Oct 1;114(14):3024-32. doi: 10.1182/blood-2009-01-197871. Epub 2009 May 8.

44.

Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability.

Meloni G, Mancini M, Gianfelici V, Martelli MP, Foa R, Falini B.

Haematologica. 2009 Feb;94(2):298-300. doi: 10.3324/haematol.2008.000059. No abstract available. Erratum in: Haematologica. 2009 Aug;94(8):1182.

45.

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.

Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, Gasparini P, Perrone F, Modena P, Pastorino U, Carbone A, Fabbri A, Sidoni A, Nakamura S, Gambacorta M, Fernández PL, Ramirez J, Chan JK, Grigioni WF, Campo E, Pileri SA, Falini B.

Am J Pathol. 2009 Feb;174(2):661-70. doi: 10.2353/ajpath.2009.080755. Epub 2009 Jan 15.

46.

Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm.

Facchetti F, Pileri SA, Agostinelli C, Martelli MP, Paulli M, Venditti A, Martelli MF, Falini B.

Haematologica. 2009 Feb;94(2):285-8. doi: 10.3324/haematol.13855. Epub 2008 Dec 9.

47.

A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF.

Bolli N, De Marco MF, Martelli MP, Bigerna B, Pucciarini A, Rossi R, Mannucci R, Manes N, Pettirossi V, Pileri SA, Nicoletti I, Falini B.

Leukemia. 2009 Mar;23(3):501-9. doi: 10.1038/leu.2008.326. Epub 2008 Nov 13.

PMID:
19005479
48.

Transformation by retroviral vectors of bone marrow-derived mesenchymal cells induces mitochondria-dependent cAMP-sensitive reactive oxygen species production.

Piccoli C, Scrima R, Ripoli M, Di Ianni M, Del Papa B, D'Aprile A, Quarato G, Martelli MP, Servillo G, Ligas C, Boffoli D, Tabilio A, Capitanio N.

Stem Cells. 2008 Nov;26(11):2843-54. doi: 10.1634/stemcells.2007-0885. Epub 2008 Sep 11.

49.

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).

Liso A, Castiglione F, Cappuccio A, Stracci F, Schlenk RF, Amadori S, Thiede C, Schnittger S, Valk PJ, Döhner K, Martelli MF, Schaich M, Krauter J, Ganser A, Martelli MP, Bolli N, Löwenberg B, Haferlach T, Ehninger G, Mandelli F, Döhner H, Michor F, Falini B.

Haematologica. 2008 Aug;93(8):1219-26. doi: 10.3324/haematol.13209. Epub 2008 Jul 4.

50.

Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family.

Cazzaniga G, Lo Nigro L, Cifola I, Milone G, Schnittger S, Haferlach T, Mirabile E, Costantino F, Martelli MP, Mastrodicasa E, Di Raimondo F, Aversa F, Biondi A, Falini B.

Leukemia. 2009 Jan;23(1):199-203. doi: 10.1038/leu.2008.170. Epub 2008 Jul 3. No abstract available.

PMID:
18596743

Supplemental Content

Loading ...
Support Center